Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus | Zendy

Megan L. Troxell | Zendy; Charles D. Bangs | Zendy; Helen J. Lawce | Zendy; Ilana Galperin | Zendy; Daniel Baiyee | Zendy; Robert B. West | Zendy; Susan B. Olson | Zendy; Athena M. Cherry | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus

Author(s) -

Megan L. Troxell,

Charles D. Bangs,

Helen J. Lawce,

Ilana Galperin,

Daniel Baiyee,

Robert B. West,

Susan B. Olson,

Athena M. Cherry

Publication year - 2006

Publication title -

american journal of clinical pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.859

H-Index - 128

eISSN - 1943-7722

pISSN - 0002-9173

DOI - 10.1309/9eym6ve58f2ycd9f

Subject(s) - fluorescence in situ hybridization , centromere , biology , chromosome 17 (human) , immunohistochemistry , polysomy , locus (genetics) , amplicon , chromosome , microbiology and biotechnology , marker chromosome , breast carcinoma , pathology , genetics , breast cancer , karyotype , gene , cancer , medicine , immunology , polymerase chain reaction

Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (<2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research